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ABSTRACT 
Comparisons of systemic exposure to toxicants during monitored cigarette smoking, electronic 
cigarette (e-cigarette) use and abstention are needed to enhance our understanding of the risks of 
e-cigarette use (vaping). In a crossover study, we measured 10 mercapturic acid metabolites of 
volatile organic compounds (VOCs) in 24-h urine samples collected from 36 dual users (8 
women) of e-cigarettes and cigarettes during two days of ad libitum vaping or cigarette-only use, 
and two days of enforced abstention. Concentrations of VOC metabolites were higher during 
smoking compared to vaping, except for the methylating agents metabolite. The fold-difference 
in concentrations when smoking relative to vaping ranged from 1.31 (1.06-1.61) (GM, 95% CI) 
(1,3-butadiene) to 7.09 (5.88-8.54) (acrylonitrile). Metabolites of acrylamide [fold difference of 
1.21 (1.03-1.43)] and benzene [1.46 (1.13-1.90)] were higher during vaping compared to 
abstention. The 1,3-butadiene and propylene oxide metabolites were higher in variable-power 
tank users compared to users of cig-a-likes. E-cigarettes expose users to lower levels of toxic 
VOCs compared to cigarette smoking, supporting their harm reduction potential among smokers. 
However, some e-cigarettes expose users to VOCs such as acrylamide, benzene, and propylene 
oxide, and may pose health risks to nonsmoking users. The results of our study will inform 
regulators in assessing e-cigarettes with respect to the balance between its potential harm 
reduction for adult smokers and risk to nonsmoking users. 
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INTRODUCTION 
 Although nicotine is the primary addictive substance in tobacco smoke (1), and despite 
concerns about nicotine’s potential deleterious effects (2, 3), the morbidity and mortality of 
smoking are attributable primarily to non-nicotine toxicants such as volatile organic compounds 
(VOCs) (4, 5). As such, cigarettes and other combustible tobacco products are the most harmful 
on the continuum of risk of tobacco products. On the other hand, noncombustible tobacco 
products, such as electronic cigarettes (e-cigarettes), are believed to be less harmful because their 
emissions contain low levels or none of the many toxicants present in tobacco smoke (6). Based 
on these observations, the harm reduction potential of e-cigarettes has been proposed by some, 
including the Food and Drug Administration (7), as a way to reduce the public health burden of 
smoking. A further important consideration is the inherent toxicity of e-cigarettes and the 
potential risks they pose to nonsmokers who vape.  
In general, e-cigarette users have lower systemic exposure to toxicants compared to 
smokers, which supports the idea that e-cigarettes have a lower risk profile relative to cigarettes 
(6). These findings have been largely derived from studies in which e-cigarette-naïve smokers 
switched from cigarettes to e-cigarettes and were followed prospectively in their naturalistic 
settings (i.e., switching studies), and include assessing changes in biomarkers of tobacco-related 
toxicants (8-11). Additionally, cross-sectional comparisons of biomarkers of toxicant exposure in 
smokers and e-cigarette users who used their products in their naturalistic settings have been 
reported (12-15). Important limitations of these studies are that product use (and patterns of use) 
are not controlled or monitored, are self-reported, and potentially include use of multiple tobacco 
products, making it difficult to ascertain e-cigarette use and quantify the magnitude of e-
cigarette-associated exposures and the risk of e-cigarette-only use. More accurate assessment of 
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toxicant exposure associated with e-cigarette-only use relative to cigarette smoking or no product 
use will enhance our understanding of the public health risk of e-cigarettes. One between-subject 
industry study found no significant differences in levels of VOC metabolites in smokers who 
used blu® e-cigarettes exclusively for 5 days in a research setting compared to smokers who 
were abstinent over that same period (11).  
The primary objective of the present study was to assess one aspect of e-cigarette safety 
by measuring urinary biomarkers of toxic and/or carcinogenic VOCs in a crossover (within-
subject) study where each participant used e-cigarettes only, cigarettes only, and had a period of 
enforced nicotine and tobacco product abstention. Biochemical measures included mercapturic 
acid metabolites of acrolein, which is believed to be a major contributor to smoking-induced 
cardiopulmonary disease (5) and is a thermal breakdown product of glycerin in e-cigarettes (16), 
benzene, a known human carcinogen (17) that can be formed from e-cigarette constituents such 
as benzoic acid (18), and propylene oxide, an International Agency for Research on Cancer 
(IARC) class 2B carcinogen (possibly carcinogenic to humans) (19) that can be formed by 
thermal degradation of propylene glycol (20).  
 
MATERIALS AND METHODS  
Study Design 
We conducted a two-arm counterbalanced, crossover study in 36 healthy dual users of e-
cigarettes and cigarettes. Participants were asked to smoke cigarettes or vape e-cigarettes only 
for periods of seven days, each. During each arm, use of the assigned product and subjective 
measures were tracked by self-report for four days as outpatients, followed by three days on a 
research ward where product use was monitored or abstention enforced, and biosamples were 
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collected for biomarker measurement. The hospital phase of each arm included a single-dose 
pharmacokinetic study on the first day of admission (21), followed by two days of ad libitum 
access to the assigned product. Further, two days of enforced abstention on the research ward 
were added immediately after the second arm to examine excretion of toxicant biomarkers 
during a period of no tobacco product use. In this study, we present biomarkers of toxicants 
measured in spot urine samples collected at baseline (before product assignment), in 24-hour 
urine samples collected during the two days of ad libitum access to the assigned product during 
each arm and in 24-hour urine samples collected on the second of 2 days of abstention. Known 
elimination half-lives of the VOC mercapturic acid metabolites measured are 8 hours for the 
acrylonitrile metabolite (CNEMA (22)), 9 hours for the acrolein (3-HPMA (23)) and benzene 
metabolites (PMA, (24)) and 14 hours for the acrylamide metabolite (AAMA, (23) (see the 
Analytical Chemistry section for full names of the metabolites). Although VOC metabolite levels 
derived from noncompliant smoking during the at-home period of the e-cigarette arm would 
potentially carryover to levels measured during e-cigarette use on the research ward, or smoking 
during the second arm on the research ward would potentially carryover to the abstention arm, 2 
to 3 days of abstention from cigarettes are sufficient to observe substantial reductions in urinary 
mercapturic acid levels to near baseline (25).  
 
Participants  
 Thirty-six healthy participants recruited via Craigslist.com, Facebook, flyers, and college 
campus newspapers, completed the study. Participants had to be at least 21 years old, smoke at 
least 5 cigarettes per day (CPD) over the past 30 days and use the same e-cigarette device at least 
once daily on 15 of the past 30 days, use e-liquids of at least 6 mg/mL nicotine concentration; 
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have no intention to quit smoking or vaping, and at screening, have saliva cotinine and expired 
carbon monoxide (CO) of ≥ 50 ng/mL and ≥ 5 ppm, respectively, negative pregnancy test (if a 
woman), and negative urine illicit drug test, except for cannabis. The study was conducted in 
accordance with the principles of the Declaration of Helsinki, and the protocol was approved by 
the Institutional Review Board at the University of California San Francisco. Written, informed 
consent was obtained from each participant and all participants were financially compensated. 
 
Products 
 Participants used their usual brands of e-cigarettes and cigarettes, provided by the study. 
The types of e-cigarettes used by study participants were as follows: cig-a-likes (n=12 
participants); fixed-power tanks (n=15), variable-power tanks (n=6) and, pod e-cigarettes (n=3, 
all JUULs). Details of the products have been described elsewhere (21).  
 
Experimental procedure 
 We screened participants for eligibility in an outpatient research clinic where consent was 
obtained, questionnaires completed, and saliva samples were collected for cotinine measurement. 
Eligible participants returned for an orientation visit at which time the sequence of products was 
assigned, and a four-day supply of the product assigned to the first arm was dispensed for at-
home use. During the orientation visit, we also collected a spot urine sample for baseline 
assessment of exposure biomarkers.  
 On Day 5 of each arm, participants were admitted to one of the Clinical Research Center 
(CRC) research smoking rooms at the Zuckerberg San Francisco General Hospital (ZSFG) 
between 7:00 to 8:00 AM. We asked participants to abstain from all tobacco product use starting 
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at 10 PM the night before the hospital admission and we measured expired CO to verify 
abstinence from cigarettes (≤ 5 ppm). An intravenous (IV) line for blood sampling was placed in 
the forearm followed by a standardized session of product use to examine differences in nicotine 
pharmacokinetics and subjective effects between e-cigarettes and cigarette use (21). 
 During the second and third days of admission (of each arm), participants had ad libitum 
access to the assigned product from 8 AM to midnight (hospital policy prohibits smoking in the 
hospital smoking rooms after midnight). For these two days of ad libitum use (referred hereafter 
as ad libitum Day 1 and Day 2), cig-a-like users were given their usual brand of cartridges, fixed-
power or variable-power tank users were provided with their usual brand of e-liquid in a vial, 
which they used with their own device, and JUUL users were provided with their usual flavor of 
JUUL pods. During the cigarette arm, participants were given their usual brand of cigarettes. 
Since the participants were dual users, in order to meet their required daily nicotine intake, we 
anticipated an increased consumption of the assigned product compared to self-reported 
consumption of that product during the screening visit. Accordingly, participants were given an 
additional number of cartridges, e-liquid vials, pods or cigarettes during these two ad libitum 
access days. All remaining products were collected by study nurses at midnight. No participant 
ran out of their cartridges, e-liquids, pods or cigarettes during the day. After the second study 
arm, participants remained for an additional two days, during which they abstained from any 
nicotine or tobacco products.  Twenty-four-hour urine was collected on the two days of ad 
libitum access of each arm and on the last day of abstention.  
 
Analytical chemistry 
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We measured mercapturic acid metabolites of VOCs in urine samples using liquid 
chromatography with tandem mass spectrometry (LC-MS/MS) by a method previously described 
(26). The mercapturic acid metabolites measured were as follows, shown as the mercapturic acid 
metabolite [abbreviation, parent compound(s), limit of quantitation (LOQ)]: 2-
hydroxypropylmercapturic acid [2-HPMA, propylene oxide, 0.5 ng/mL]; 3-
hydroxypropylmercapturic acid [3-HPMA, acrolein, 1 ng/mL]; 2-carbamoylethylmercapturic 
acid [AAMA, acrylamide, 0.5 ng/mL]; 2-cyanoethylmercapturic acid [CNEMA, acrylonitrile, 
0.5 ng/mL]; 2-hydroxyethylmercapturic acid [HEMA, acrylonitrile, vinyl chloride, ethylene 
oxide, 0.5 ng/mL]; 3-hydroxy-1-methylpropylmercapturic acid [HPMMA, crotonaldehyde, 1 
ng/mL]; sum of isomers 1-hydroxy-3-buten-2-yl-mercapturic acid and 2-hydroxy-3-buten-1-yl-
mercapturic acid [MHBMA-1+2, 1,3-butadiene, 0.1 ng/mL]; 4-hydroxy-2-buten-1-yl-
mercapturic acid [MHBMA-3, 1,3-butadiene, 0.1 ng/mL]; methylmercapturic acid [MMA, 
methylating agents such as 4-(methylnitrosamino)-1-(3-pyridyl)-1- butanone (NNK), N-
nitrosodimethylamine (NDMA), and endogenous methylating agents, 5 ng/mL]; and 
phenylmercapturic acid [PMA, benzene, 0.1 ng/mL].  
 
Statistical analysis 
 We imputed biomarker values below the LOQ using the LOQ divided by the square root 
of 2 (LOQ/√2) and we normalized urinary biomarker concentrations by creatinine 
concentrations, including biomarkers measured in 24-h urine. We normalized the 24-h urine 
samples for creatinine since the spot urine sample collected at baseline had to be normalized for 
creatinine. However, differences in 24-h urinary biomarker levels across arms were consistent 
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with or without creatinine correction. Since the concentrations were approximately log-normally 
distributed, biomarker concentrations were log-transformed.  
Our primary analysis was a comparison of Day 2 urinary biomarker concentrations over 
the three conditions via repeated measures ANCOVA. We focused on Day 2 because, as stated 
before, VOC metabolite concentrations derived from noncompliant smoking during the at-home 
phase of the e-cigarette arm would be reduced substantially by Day 2 on the research ward. We 
conducted post-hoc pairwise comparisons between study arms and applied Bonferonni correction 
for multiple comparisons. Covariates included sex and treatment order and a random effect of 
participants. We calculated geometric mean and 95% confidence intervals for the relative ratio of 
concentrations in cigarette vs e-cigarette arms and e-cigarette vs abstention. We evaluated 
differences in urinary biomarker levels on Day 2 between e-cigarette device types with Wilcoxon 
Rank-Sum Tests. We computed Spearman correlation coefficients between 24-h biomarker 
concentrations and corresponding 24-h area under the plasma nicotine concentration-time curve 
(AUC) for the e-cigarette and cigarette arms, respectively, as a way to examine the relationship 
between product use on the research ward and VOC exposure. (Plasma nicotine AUC is reported 
in another manuscript (27)). Finally, we computed the frequencies of participants with e-cigarette 
to abstention relative biomarker level ratios of at least 1.25 or at least 1.50 by device type and 
flavor category, representing at least 25% and 50% higher biomarker levels from e-cigarette use 
compared to abstention. 
  All analyses were considered significant at two-tailed p-values of < 0.05 and were 
conducted in SAS Version 9.4 and R Version 3.4. 
 
RESULTS 
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 Of 36 participants enrolled (8 women), 2 were Asian, 3 were African American/Black, 4 
were Latino, 22 were White, and 5 were mixed-race. On average, participants smoked 12.9 ± 6.4 
(mean ± SD) CPD, used e-cigarettes on 22.6 ± 7.3 days of the past 30 days, and on days that they 
used the e-cigarette, they used the e-cigarette 8.1 ± 7.2 times. Average screening saliva cotinine 
was 189 ± 92.8 ng/mL (range 119 to 248 ng/mL). Eight participants (22.2%) used a 
dessert/candy flavored e-liquid/e-cigarette, 5 (13.9%) used a fruit flavor, 5 (13.9%) used a 
menthol flavor and 18 (50%) used a tobacco flavor. 
 
VOC exposure from e-cigarettes vs cigarettes 
 Concentrations of metabolites of VOCs collected in spot urine samples at baseline and in 
24-hour urine collected during ad libitum use of the assigned product on Day 1 and Day 2, 
respectively, and during enforced abstention are shown in Figure 1a-1j. Table 1 shows these 
VOC metabolite concentrations in 24-hour urine collected on Day 2 during e-cigarette or 
cigarette use and during abstention. Concentrations of all VOC metabolites were significantly 
higher during both days of cigarette use compared to e-cigarette use (all p values < 0.001) except 
for MMA (the metabolite of methylating agents) (Figure 1a-1j). The geometric means of the 
fold-difference in concentrations of these VOC metabolites when using cigarettes relative to that 
of e-cigarettes ranged from 1.31 for MHBMA-3 (one of the butadiene metabolites) to 7.09 for 
CNEMA (acrylonitrile metabolite) (Table 2).  
 
VOC exposure from e-cigarettes vs abstinence  
Within-subject concentrations of metabolites of acrylamide (AAMA) and benzene 
(PMA) were significantly higher during e-cigarette use (Day 2 of the e-cigarette arm) compared 
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to abstention, with average within-subject fold-difference of 1.21 (p = 0.019) and 1.46 (p = 
0.006), respectively among all participants (Table 1). Considering the absolute concentration of 
each metabolite, compared to abstention, most participants had higher levels of AAMA 
(frequency = 63.9%), PMA (66.7%), and 2-HPMA (58.3%) during e-cigarette use (Figure 2a, 2b, 
and 2c). Metabolites of acrylonitrile (CNEMA), 1,3-butadiene (MHBMA-1+2), and ethylene 
oxide (HEMA) were significantly lower during e-cigarette use than during abstention, with 
average fold-differences of 0.64 (p < 0.001), 0.63 (p = 0.001), and 0.82 (p = 0.010), respectively.  
The order of assigned products influenced the magnitude of changes in the concentrations 
of some metabolites measured during e-cigarette use compared to abstention, indicative of 
potential carryover effect on biomarker levels from smoking cigarettes (Table 1 and Figure 2d, 
2e, and 2f). The within-subject fold-difference from e-cigarette use compared to abstention in 
concentrations of metabolites of acrylamide, benzene and propylene oxide were higher in 
participants who used e-cigarettes during the second arm (i.e., immediately before the abstinence 
days) compared to those who smoked cigarettes during the second arm (Table 1). Of note, the 
average concentration of the benzene metabolite (PMA) was 2.18-fold higher during e-cigarette 
use relative to abstention among participants who were assigned e-cigarettes during the second 
arm while it was a 0.94-fold-difference in participants who smoked cigarettes during the second 
arm.  
 
VOC exposure across different types of e-cigarettes 
 In Table 2, we present concentrations of VOC metabolites across users of different types 
of e-cigarettes during the e-cigarette arm. When all participants were considered, the 1,3-
butadiene metabolite (MHBMA-3) and the propylene oxide metabolite (2-HPMA) were 
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significantly different across e-cigarette devices, with higher levels in variable-power tank users. 
When pod users were excluded from the analysis, 2-HPMA was the only VOC metabolite that 
differed significantly by device type.  
 
Correlations between VOCs and nicotine exposure 
 Spearman correlation coefficients between VOC metabolite levels and plasma nicotine 
AUC over 24 h for Day 2 of the cigarette and e-cigarette arms are shown in Table 3. For the 
cigarette arm, except for MHBMA-1+2 (1,3-butadiene) and MMA (methylating agents), 
correlation between plasma nicotine AUC and urinary VOC metabolites was moderate and 
statistically significant. For the e-cigarette arm, the correlation between plasma nicotine AUC 
and 2-HPMA (propylene oxide) was small and statistically significant but others were not 
significant. 
 
Evaluation of elevated exposures from e-cigarette use by device type and flavors  
 We present the frequency of participants whose biomarker levels were at least 25% 
(Table 4, Section A) or 50% (Table 4, Section B) higher during e-cigarette use relative to 
abstention by device types and e-liquid flavors. Notably, 21 (58.3%) of 36 participants had at 
least 50% higher PMA (benzene) levels during e-cigarette use compared to abstention, including 
8 of 12 (66.7%) cig-a-like users, 8 of 15 (53.3%) fixed-power tank users, 3 of 6 (50%) variable-
power tank users, and 2 of 3 (66.7%) pod users. Across flavors, 3 of 8 (37.5%) users of 
dessert/candy e-liquids, 5 of 5 (100%) users of fruit flavors, 3 of 5 (60%) users of menthol 
flavor, and 11 of 18 (61.1%) users of tobacco flavors had PMA levels that were at least 50% 
higher during e-cigarette use than abstention.   
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DISCUSSION 
 The public health burden of e-cigarette use is a balance between their potential benefits as 
a form of harm reduction for smokers and their direct harms to nonsmokers who vape. The 
findings of our study support the harm reduction potential of e-cigarettes for smokers but also 
suggest that e-cigarettes may have deleterious effects in non-smoking vapers. We found that dual 
users confined to a research ward were exposed to substantially lower levels of toxic and/or 
carcinogenic VOCs when they used e-cigarettes compared to when they smoked cigarettes. 
These findings align with previous cross-sectional studies and longitudinal ambulatory switching 
studies which found that e-cigarette use resulted in lower systemic exposure to toxicants 
compared to smoking (10, 12).  
Of note however, we found higher levels of metabolites of acrylamide, benzene, and 
possibly propylene oxide during e-cigarette use relative to enforced abstention, suggesting that e-
cigarette use results in higher systemic exposure to these toxic/carcinogenic VOCs. These 
findings are important because, as far as we know, this is the first non-industry-associated 
assessment of toxicant exposure from use of commercial e-cigarettes in a setting where e-
cigarette use is monitored and abstention enforced.  
We found no published study explaining how e-cigarette use can lead to increased 
exposure to acrylamide, an IARC Group 2A carcinogen (probable human carcinogen). Sources 
of acrylamide exposure include manufacturing, chemical, and agricultural industries, but French 
fries, potato chips, cereals, and coffee are important dietary sources (28). Acrylamide is 
generated through the Maillard reactions of food products, which are heat-dependent reactions of 
glucose with amino acids, particularly asparagine, peptides and aromatic amines (29, 30). These 
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reactions are plausible during e-cigarette use. Amino acids are not a significant constituent of e-
liquids but studies have reported greater excretion of aromatic amines from exclusive e-cigarette 
users compared to controls (31), suggesting that aromatic amines are given off in e-cigarette 
aerosols and might contribute to acrylamide formation. Another potential pathway of acrylamide 
formation is the reaction between acrylic acid, formed from oxidation of acrolein, and ammonia, 
which could be potentially generated by thermal decomposition of nitrogen-containing 
compounds (29). Of relevance to the latter route, ethyl acrylate, the ethyl ester of acrylic acid, is 
a major volatile constituent of organic passion fruit pulp (32), is found in pineapples, grapes and 
vanilla (33), and is a flavor additive (34). Ethyl acrylate would react with ammonia much more 
readily than would acrylic acid. Furthermore, since acrylamide is used in the manufacture of 
some plastics and adhesives, we cannot rule out the possibility that acrylamide residues that 
remain in plastics used in the manufacture of e-cigarette devices or in plastic equipment and 
containers used in manufacturing and transporting of e-liquids is the source.  
We did not see a significant correlation between plasma nicotine AUC over 24 h and 24-
h urinary AAMA levels during the e-cigarette arm, suggesting that other sources could have 
contributed to acrylamide exposure. Also, the elimination half-life of AAMA is 14 hours (23), 
thus noncompliant smoking during the at-home phase of the e-cigarette arm could have 
influenced AAMA levels measured during the research ward phase of the e-cigarette arm. 
Nevertheless, during the smoking arm, there was no increase in AAMA levels from Day 1 to 
Day 2 (Figure 1a-1j), arguing against substantial carryover effect of smoking on AAMA levels. 
Further, among those who were assigned the e-cigarette during the second arm, AAMA levels 
were significantly higher during e-cigarette use compared to abstention, providing evidence of 
the contribution of e-cigarettes to acrylamide exposure. In summary, acrylamide formation in e-
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cigarettes is plausible and our findings are suggestive, but a firm conclusion cannot be made that 
e-cigarette use leads to acrylamide exposure.  
Pankow and colleagues demonstrated that benzene can be generated from thermal 
degradation of the humectants, propylene glycol (PG) and vegetable glycerin (VG), and 
additives, such as benzoic acid and benzaldehyde (18). Most participants with elevated levels of 
the benzene metabolite (PMA) during e-cigarette use relative to abstention were users of cig-a-
likes or fixed-power e-cigarettes (i.e. low-powered devices); users of fruit or tobacco flavors also 
showed elevated benzene exposure. Although generation of aldehydes and VOCs in e-cigarette 
aerosol is known to be temperature dependent (16), and thus higher exposure to these toxicants 
are expected in users of high-powered devices, our study raises questions about toxicant 
exposure from use of low-powered devices. Benzene has been detected in some refill e-liquids 
and cartridges (35), potentially serving as a source of benzene even in devices that operate at low 
power/temperature settings.   
Users of variable-power e-cigarettes, which are typically operated at higher power and 
temperatures (36), had elevated excretion of the propylene oxide metabolite (2-HPMA) 
compared to users of the other types of e-cigarettes. Propylene oxide, an IARC Group 2B 
carcinogen (possibly carcinogenic to humans) (19), can be derived from propylene glycol in the 
presence of weak bases and heat (37). Aerosol generation is greater in high power e-cigarettes, 
resulting in greater nicotine intake and potentially more propylene oxide generation. The 
significant correlation between 2-HPMA levels and plasma nicotine AUC during the e-cigarette 
arm is evidence for propylene oxide generation in e-cigarettes.   
We found no evidence of significant differences in exposure to the other VOCs, including 
acrolein, across device types. This observation regarding acrolein was surprising since vaping 
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machine studies have reported substantial acrolein generation from e-cigarettes, particularly at 
higher power settings (38-40). However, it is possible that background exposure to acrolein, 
primarily from food sources through thermal breakdown of animal and vegetable fats, 
carbohydrates, and amino acids, or even endogenous production of acrolein (41), could 
overwhelm the contribution of e-cigarettes to acrolein exposure. To minimize the contribution of 
food to toxicant exposure during the participants’ stay on the research ward, we did not allow 
charbroiled meats and fried foods. Further, since participants were admitted to the hospital on the 
same day of each week, they were served the same meals on each named day, thus reducing 
variation in diet-related exposures within- and between-participants. 
Despite lower risks of e-cigarettes relative to cigarettes, questions remain of the inherent 
toxicity of e-cigarettes, and risks to nonsmoking adults and children who vape. Our findings of 
potentially increased systemic exposure to acrylamide, benzene, and propylene oxide from e-
cigarette use are particularly concerning given that these VOCs are known or suspected human 
carcinogens. A previous study found higher levels of another benzene metabolite, trans,trans-
muconic acid, in baseline urine samples of e-cigarette users compared to nontobacco users 
enrolled in a laboratory study, but polyuse of other tobacco products could not be ruled out (15). 
Our findings also raise concerns about benzene exposure among JUUL users since a major 
constituent of JUUL pod fluids is benzoic acid. Although the study by Pankow and colleagues 
did not detect benzene in JUUL aerosol, 2 of 3 JUUL users in our study had elevated PMA 
excretion during e-cigarette use relative to abstention.  
Using the same analytical chemistry methods as used in the current study, we measured 
all ten VOC metabolites in smokers enrolled in a clinical trial at 10 sites across the U.S. Levels 
of all metabolites in smokers in the former study were comparable to levels measured at baseline 
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and during the cigarette arm in the current study (42). In addition, of the same eight VOC 
biomarkers utilized between studies, average levels of 2-HPMA, 3-HPMA, and HEMA 
measured in e-cigarette-only users from a nationally-representative sample were comparable to 
levels measured during the e-cigarette arm of the current study; the average level of AAMA was 
about two times higher and CNEMA was over 5 times higher during the e-cigarette arm of the 
current study while the average levels of HPMMA, MHBMA-1+2, and PMA were 2.6, 8, and 2 
times higher, respectively, in e-cigarette-only users in the former study compared to during the e-
cigarette arm of the current study (12). 
A strength of our study is its crossover design, in which each participant served as their 
own control. However, while we counterbalanced the order of e-cigarette and cigarette arms, the 
two days of abstention always followed the second arm. Since the VOC metabolites have half-
lives of several hours, from at least 8 hours for CNEMA (acrylonitrile) (22) to 14 hours for the 
AAMA (acrylamide) (23), there was likely carryover from product use to abstention, particularly 
when cigarettes were assigned immediately before the abstention days (see Figure 2a-2f). Thus, 
we could have underestimated differences in VOC exposure from e-cigarette use compared to 
abstention. On the other hand, during the cigarette and e-cigarette arms, the levels of biomarkers 
at Day 1 and Day 2 were consistent, potentially indicating minimal carryover from one day to the 
next. Another limitation of our study is that most participants were males which limits 
assessment of sex differences. Further, assessment of differences by device type was limited by 
the small sample size of variable-power tank users and JUUL pod users enrolled in the study.  
In conclusion, e-cigarettes expose users to lower levels of toxic VOCs, supporting their 
harm reduction potential among smokers. However, some e-cigarettes potentially expose users to 
VOCs such as acrylamide, benzene, and propylene oxide, and may pose health risks to 
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nonsmoking users. For example, more cig-a-like users had elevated benzene exposure compared 
to users of other types of e-cigarettes. Further studies are needed to examine what design features 
of e-cigarettes and user behaviors lead to elevated toxicant exposure. Regulation of e-cigarettes 
must include a balanced approach to maximize their potential for harm reduction among adult 
smokers and minimize their risk to nonsmoking users, including minimizing exposure to toxic 
VOCs. 
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TABLES 
 
TABLE 1 Concentrations of mercapturic acid metabolites of volatile organic compounds (VOCs) measured in 24-hour urine collected 
during cigarette smoking, e-cigarette use, and abstention.  
 
Exposure (Biomarker)  Cigarette  E-cigarette Abstention CC to EC ratio  Ratio of EC to Abstention (GM, 95% CI) 
(ng/mg creatinine) (Mean, SD) (Mean, SD) (Mean, SD) (GM, 95% CI) All subjects CC at Arm 2* EC at Arm 2** 
Acrolein (3-HPMA) 965.7 (674.3) 258.8 (195.2) 279.9 (140.0) 3.70 (2.85-4.79) a 0.82 (0.67-1.01) 0.81 (0.62-1.04) 0.83 (0.61-1.14) 
Acrylamide (AAMA) 190.2 (72.8) 112.9 (50.8) 92.8 (37.2) 1.70 (1.50-1.92) a 1.21 (1.03-1.43) b 1.15 (0.93-1.43) 1.27 (1.01-1.61) 
Acrylonitrile (CNEMA) 140.9 (95.5) 21.8 (19.7) 32.9 (27.6) 7.09 (5.88-8.54) a 0.64 (0.56-0.74) c 0.50 (0.42-0.59) 0.81 (0.71-0.92) 
1,3-Butadiene (MHBMA-1+2) 3.43 (3.23) 0.51 (0.42) 0.70 (0.40) 5.80 (3.73-9.00) a 0.63 (0.48-0.82) c 0.47 (0.32-0.68) 0.83 (0.61-1.13) 
1,3-Butadiene (MHBMA-3) 0.21 (0.12) 0.17 (0.13) 0.15 (0.10) 1.31 (1.06-1.61) a 1.05 (0.84-1.30) 0.92 (0.66-1.29) 1.18 (0.91-1.53) 
Benzene (PMA) 1.77 (1.52) 0.48 (0.31) 0.42 (0.48) 3.21 (2.53-4.07) a 1.46 (1.13-1.90) b 0.94 (0.64-1.37) 2.18 (1.71-2.77) 
Crotonaldehyde (HPMMA) 489.9 (297.7) 168.1 (95.36) 145.6 (55.3) 2.77 (2.34-3.29) a 1.08 (0.94-1.25) 1.23 (0.99-1.54) 0.97 (0.82-1.14) 
Ethylene oxide (HEMA) 4.28 (3.82) 1.47 (1.06) 1.84 (1.64) 2.55 (2.10-3.10) a 0.82 (0.71-0.95) c 0.78 (0.66-0.93) 0.86 (0.69-1.08) 
Methylating agent (MMA) 15.51 (12.84) 17.30 (20.32) 18.0 (17.5) 1.01 (0.85-1.20) 0.94 (0.77-1.15) 1.18 (0.97-1.44) 0.77 (0.57-1.04) 
Propylene oxide (2-HPMA) 82.7 (43.5) 53.6 (41.1) 41.7 (22.9) 1.69 (1.33-2.16) a 1.17 (0.98-1.39) 1.08 (0.88-1.33) 1.24 (0.95-1.64) 
Notes: * CC at Arm 2 = participants who were assigned to smoke combustible cigarettes during Arm 2 immediately before the abstention days; **EC at Arm 2 = 
participants who were assigned to vape e-cigarettes during Arm 2, immediately before the abstention days; a = significant difference between combustible 
cigarettes and e-cigarettes; b = significantly higher during e-cigarette use compared to abstention; c = significantly lower during e-cigarette use compared to 
abstention; 2-HPMA = 2-hydroxypropylmercapturic acid; 3-HPMA = 3-hydroxypropylmercapturic acid; AAMA = 2-carbamoylethylmercapturic acid; CNEMA 
= 2-cyanoethylmercapturic acid; HEMA = 2-hydroxyethylmercapturic acid (acrylonitrile, vinyl chloride, ethylene oxide); HPMMA = 3-hydroxy-1-methyl-
propylmercapturic acid; MHBMA-1+2 = sum of isomers 1-hydroxy-3-buten-2-yl-mercapturic acid and 2-hydroxy-3-buten-1-yl-mercapturic acid; MHBMA-3 = 
4-hydroxy-2-buten-1-yl-mercapturic acid; MMA = methylmercapturic acid; and, PMA = phenylmercapturic acid. During Day 2 of the cigarette arm, per cent 
below the limit of quantitation (LOQ) for each metabolite was as follows: 3-HPMA (0%); AAMA (0%); CNEMA (0%); MHBMA-1+2 (2.8%); MHBMA-3 
(58.3%); PMA (0%); HPMMA (0%); HEMA (0%); MMA (36.1%); 2-HPMA (0%). Per cent below LOQ on Day 2 of the e-cigarette arm were as follows: 3-
HPMA (0%); AAMA (0%); CNEMA (0%); MHBMA-1+2 (41.7%); MHBMA-3 (83.3%); PMA (22.2%); HPMMA (0%); HEMA (0%); MMA (33.3%); 2-
HPMA (0%). Per cent below LOQ during abstinence were as follows: 3-HPMA (0%); AAMA (0%); CNEMA (0%); MHBMA-1+2 (80.6%); MHBMA-3 
(97.2%); PMA (30.6%); HPMMA (0%); HEMA (25.0%); MMA (33.3%); 2-HPMA (0%). 
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TABLE 2 Concentrations of mercapturic acid metabolites of volatile organic compounds (VOCs) measured in 24-hour urine during e-
cigarette use  
 
Exposure (Biomarker) 
(ng/mg creatinine) 
Cig-a-like 
(mean, SD) 
(n = 12) 
Fixed-power 
(mean, SD) 
(n = 15) 
Variable-power 
(mean, SD) 
(n = 6) 
Pod  
(mean, SD) 
(n = 3) 
Difference (p value) 
All 
included 
Pods  
excluded 
Acrolein (3-HPMA) 260.6 (236.0) 238.7 (189.8) 340.7 (173.1) 188.0 (49.9) 0.081 0.100 
Acrylamide (AAMA) 117.4 (65.9) 103.2 (43.6) 118.8 (35.1) 131.9 (58.9) 0.325 0.311 
Acrylonitrile (CNEMA) 27.5 (28.6) 20.8 (15.6) 17.1 (3.79) 13.1 (13.4) 0.442 0.950 
1,3-Butadiene (MHBMA-1+2) 0.51 (0.36) 0.57 (0.50) 0.50 (0.43) 0.19 (0.07) 0.055 0.730 
1,3-Butadiene (MHBMA-3) 0.16 (0.09) 0.15 (0.09) 0.24 (0.23) 0.08 (0.05) 0.019 0.363 
Benzene (PMA) 0.54 (0.22) 0.48 (0.41) 0.38 (0.20) 0.39 (0.19) 0.081 0.129 
Crotonaldehyde (HPMMA) 152.4 (68.0) 194.2 (128.6) 132.5 (30.5) 171.3 (71.6) 0.477 0.242 
Ethylene oxide (HEMA) 1.56 (0.64) 1.35 (1.25) 1.73 (1.31) 1.27 (1.40) 0.090 0.124 
Methylating agent (MMA) 15.7 (9.3) 18.8 (27.0) 18.7 (23.7) 13.6 (12.8) 0.601 0.865 
Propylene oxide (2-HPMA) 34.2 (17.4) 62.6 (55.0) 75.8 (26.4) 42.2 (19.6) <0.001 0.001 
Notes: 2-HPMA = 2-hydroxypropylmercapturic acid; 3-HPMA = 3-hydroxypropylmercapturic acid; AAMA = 2-carbamoylethylmercapturic acid; CNEMA = 2-
cyanoethylmercapturic acid; HEMA = 2-hydroxyethylmercapturic acid (acrylonitrile, vinyl chloride, ethylene oxide); HPMMA = 3-hydroxy-1-methyl-
propylmercapturic acid; MHBMA-1+2 = sum of isomers 1-hydroxy-3-buten-2-yl-mercapturic acid and 2-hydroxy-3-buten-1-yl-mercapturic acid; MHBMA-3 = 
4-hydroxy-2-buten-1-yl-mercapturic acid; MMA = methylmercapturic acid; and, PMA = phenylmercapturic acid. 
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TABLE 3 Spearman correlation coefficients between mercapturic acid metabolites of volatile 
organic compounds (VOCs) measured in urine collected during a day of combustible cigarette 
smoking or e-cigarette use and area under the plasma nicotine concentration-time curve (AUC) 
measured during the corresponding day.  
Exposure (Biomarker) 
Plasma nicotine during 
cigarette smoking  
Plasma nicotine during  
e-cigarette use  
Spearman p value Spearman p value 
Acrolein (3-HPMA) 0.42 0.011 0.31 0.066 
Acrylamide (AAMA) 0.47 0.004 0.13 0.456 
Acrylonitrile (CNEMA) 0.53 0.001 0.14 0.428 
1,3-Butadiene (MHBMA-1+2) 0.27 0.107 0.18 0.295 
1,3-Butadiene (MHBMA-3) 0.59 <0.001 0.11 0.530 
Benzene (PMA) 0.44 0.007 0.18 0.307 
Crotonaldehyde (HPMMA) 0.43 0.008 0.29 0.084 
Ethylene oxide (HEMA) 0.20 0.244 0.16 0.352 
Methylating agent (MMA) 0.41 0.012 0.17 0.331 
Propylene oxide (2-HPMA) 0.36 0.029 0.37 0.027 
Notes: Correlations were between mercapturic acid levels measured in 24-hour urine and the area under the plasma 
nicotine concentration-time curve over 24 hours. 2-HPMA = 2-hydroxypropylmercapturic acid; 3-HPMA = 3-
hydroxypropylmercapturic acid; AAMA = 2-carbamoylethylmercapturic acid; CNEMA = 2-cyanoethylmercapturic 
acid; HEMA = 2-hydroxyethylmercapturic acid (acrylonitrile, vinyl chloride, ethylene oxide); HPMMA = 3-
hydroxy-1-methyl-propylmercapturic acid; MHBMA-1+2 = sum of isomers 1-hydroxy-3-buten-2-yl-mercapturic 
acid and 2-hydroxy-3-buten-1-yl-mercapturic acid; MHBMA-3 = 4-hydroxy-2-buten-1-yl-mercapturic acid; MMA 
= methylmercapturic acid; and, PMA = phenylmercapturic acid. 
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TABLE 4 Frequency of participants whose biomarker levels were at least 25% or 50% higher during e-cigarette use relative to 
abstention 
 
Exposure (Biomarker)  All  
E-cigarette type Flavor type 
Cig-a-like 
Fixed-
power 
Variable-
power 
Pod 
Dessert 
or Candy 
Fruit Menthol Tobacco 
Sample size (N) 36 12 15 6 3 8 5 5 18 
A. Participants with ≥25% increase in VOC biomarker levels during e-cigarette use compared to abstinence (n, %) 
Acrolein (3-HPMA) 8 (22.2) 2 (16.7) 4 (26.7) 2 (33.3) 0 (0.0) 1 (12.5) 2 (40.0) 1 (20.0) 4 (22.2) 
Acrylamide (AAMA) 17 (47.2) 6 (50.0) 6 (40.0) 3 (50.0) 2 (66.7) 3 (37.5) 3 (60.0) 3 (60.0) 9 (50.0) 
Acrylonitrile (CNEMA) 1 (2.8) 0 (0.0) 0 (0.0) 1 (16.7) 0 (0.0) 1 (12.5) 0 (0.0) 1 (20.0) 0 (0.0) 
1,3-Butadiene (MHBMA-1+2) 7 (19.4) 2 (16.7) 3 (20.0) 2 (33.3) 0 (0.0) 2 (25.0) 1 (20.0) 2 (40.0) 2 (11.1) 
1,3-Butadiene (MHBMA-3) 13 (36.1) 4 (33.3) 5 (33.3) 4 (66.7) 0 (0.0) 3 (37.5) 2 (40.0) 3 (60.0) 6 (33.3) 
Benzene (PMA) 23 (63.9) 9 (75.0) 9 (60.0) 3 (50.0) 2 (66.7) 4 (50.0) 5 (100.0) 4 (80.0) 12 (66.7) 
Crotonaldehyde (HPMMA) 15 (41.7) 5 (41.7) 6 (40.0) 2 (33.3) 2 (66.7) 5 (62.5) 2 (40.0) 5 (100) 6 (33.3) 
Ethylene oxide (HEMA) 6 (16.7) 2 (16.7) 2 (13.3) 2 (33.3) 0 (0.0) 1 (12.5) 2 (40.0) 1 (20.0) 1 (5.6) 
Methylating agent (MMA) 11 (30.6) 1 (8.3) 7 (46.7) 3 (50.0) 0 (0.0) 3 (37.5) 4 (80.0) 3 (60.0) 4 (22.2) 
Propylene oxide (2-HPMA) 18 (50.0) 6 (50.0) 8 (53.3) 3 (50.0) 1 (33.3) 2 (25.0) 5 (100.0) 2 (40.0) 10 (55.6) 
B. Participants with ≥50% increase in VOC biomarker levels during e-cigarette use compared to abstinence (n, %) 
Acrolein (3-HPMA) 4 (11.1) 0 (0.0) 2 (13.3) 2 (33.3) 0 (0.0) 1 (12.5) 0 (0.0) 1 (20.0) 3 (16.7) 
Acrylamide (AAMA) 12 (33.3) 5 (41.7) 4 (26.7) 2 (33.3) 1 (33.3) 3 (37.5) 0 (0.0) 3 (60.0) 6 (33.3) 
Acrylonitrile (CNEMA) 1 (2.8) 0 (0.0) 0 (0.0) 1 (16.7) 0 (0.0) 1 (12.5) 0 (0.0) 1 (20.0) 0 (0.0) 
1,3-Butadiene (MHBMA-1+2) 6 (16.7) 2 (16.7) 2 (13.3) 2 (33.3) 0 (0.0) 2 (25.0) 1 (20.0) 2 (40.0) 1 (5.6) 
1,3-Butadiene (MHBMA-3) 10 (27.8) 3 (25.0) 4 (26.7) 3 (50.0) 0 (0.0) 2 (25.0) 2 (40.0) 2 (40.0) 5 (27.8) 
Benzene (PMA) 21 (58.3) 8 (66.7) 8 (53.3) 3 (50.0) 2 (66.7) 3 (37.5) 5 (100.0) 3 (60.0) 11 (61.1) 
Crotonaldehyde (HPMMA) 8 (22.2) 2 (16.7) 5 (33.3) 0 (0.0) 1 (33.3) 2 (25.0) 1 (20.0) 2 (40.0) 4 (22.2) 
Ethylene oxide (HEMA) 4 (11.1) 2 (16.7) 1 (6.7) 1 (16.7) 0 (0.0) 1 (12.5) 1 (20.0) 1 (20.0) 0 (0.0) 
Methylating agent (MMA) 7 (19.4) 1 (8.3) 5 (33.3) 1 (16.7) 0 (0.0) 0 (0.0) 4 (80.0) 0 (0.0) 3 (16.7) 
Propylene oxide (2-HPMA) 11 (30.6) 3 (25.0) 5 (33.3) 3 (50.0) 0 (0.0) 1 (12.5) 4 (80.0) 1 (20.0) 6 (33.3) 
Notes: 2-HPMA = 2-hydroxypropylmercapturic acid; 3-HPMA = 3-hydroxypropylmercapturic acid; AAMA = 2-carbamoylethylmercapturic acid; CNEMA = 2-
cyanoethylmercapturic acid; HEMA = 2-hydroxyethylmercapturic acid (acrylonitrile, vinyl chloride, ethylene oxide); HPMMA = 3-hydroxy-1-methyl-
propylmercapturic acid; MHBMA-1+2 = sum of isomers 1-hydroxy-3-buten-2-yl-mercapturic acid and 2-hydroxy-3-buten-1-yl-mercapturic acid; MHBMA-3 = 
4-hydroxy-2-buten-1-yl-mercapturic acid; MMA = methylmercapturic acid; and, PMA = phenylmercapturic acid.  
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FIGURE LEGENDS 
 
FIGURE 1 Concentration of metabolites of volatile organic compounds at baseline before study 
products were assigned, during Days 1 and 2 of each arm, and during abstention from nicotine 
and tobacco products. Square brackets = significant difference between combustible cigarettes 
(CC) and e-cigarettes (EC); a = significantly lower than combustible cigarette use on Day 2; b = 
significantly lower than e-cigarette use on Day 2; c = significantly higher than e-cigarette use on 
Day 2. 2-HPMA = 2-hydroxypropylmercapturic acid; 3-HPMA = 3-hydroxypropylmercapturic 
acid; AAMA = 2-carbamoylethylmercapturic acid; CNEMA = 2-cyanoethylmercapturic acid; 
HEMA = 2-hydroxyethylmercapturic acid (acrylonitrile, vinyl chloride, ethylene oxide); 
HPMMA = 3-hydroxy-1-methyl-propylmercapturic acid; MHBMA-1+2 = sum of isomers 1-
hydroxy-3-buten-2-yl-mercapturic acid and 2-hydroxy-3-buten-1-yl-mercapturic acid; MHBMA-
3 = 4-hydroxy-2-buten-1-yl-mercapturic acid; MMA = methylmercapturic acid; and, PMA = 
phenylmercapturic acid. 
 
FIGURE 2 Within-subject changes in mercapturic acid metabolites of acrylamide (a), benzene 
(b), and propylene oxide (c) for all participants and for participants who used e-cigarettes during 
arm 2, immediately before two days of abstention, showing acrylamide (d), benzene (e), and 
propylene oxide (f). Solid black line = cig-a-like; dotted black line = fixed-power tank e-
cigarette; solid grey line = variable-power tank e-cigarette; broken grey line = JUUL pod e-
cigarette. 2-HPMA = 2-hydroxypropylmercapturic acid; AAMA = 2-carbamoylethylmercapturic 
acid; and, PMA = phenylmercapturic acid. 
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